What research is being done to improve the understanding of this ADC's mechanism?

Ongoing studies focus on detailing the interaction of the ADC with target cells, the pathways of DNA damage induced by DMDM, and the overall therapeutic window of the ADC in various models.

How does this ADC compare to full antibody ADCs in terms of therapeutic potential?

While potentially less immunogenic and more tissue-penetrant, Fab-based ADCs might exhibit different efficacy and dosing profiles compared to full antibody ADCs.

What future modifications could enhance the performance of this ADC?

Future enhancements could include optimizing the linker technology for more precise drug release or modifying the Fab fragment to improve targeting accuracy.

How is the stability of this ADC ensured during storage and transport?

The ADC must be stored under conditions that maintain the integrity of the antibody and the linker, typically requiring refrigeration and protection from light.

What are potential challenges in developing Fab fragment-based ADCs?

Challenges include ensuring the stability of the Fab fragment during conjugation, maintaining its specificity and binding affinity, and managing the overall immunogenicity of the construct.

How could the development of resistance to DMDM be addressed in therapeutic applications?

Strategies might include combination therapy with other agents to target multiple pathways, or developing ADCs with different mechanisms of action to circumvent resistance.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-HIgG(Fc)Fab-C-DMDM ADC

anti-HIgG(Fc)Fab-C-DMDM ADC (CAT#: ADC-AA-013)

This ADC product is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMDM. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, DMDM, is a cytotoxic small molecule which binds to DNA, causes DNA damage. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-human IgG Fc specific polyclonal antibody

Species Reactivity
Human

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
DMDM (duocarmycin DM)

Description
Duocarmycins belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-013. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Creative Biolabs' anti-HIgG(Fc)Fab-C-DMDM ADC has been crucial in enhancing our pre-screening for ADC candidates. The DMDM conjugate effectively causes DNA damage, facilitating rapid screening with minimal toxicity.

Excellent

We've observed significant efficiency using the anti-HIgG(Fc)Fab-C-DMDM ADC in our experiments. The ability to induce DNA damage without systemic toxicity has expedited our antibody research projects.

Excellent

The cleavable linker in the anti-HIgG(Fc)Fab-C-DMDM ADC allows for precise drug delivery, making it a superior choice for studies focusing on DNA interactions and damage. Very effective and economical for our lab's needs.

Excellent

I highly recommend the anti-HIgG(Fc)Fab-C-DMDM ADC for labs looking to streamline their ADC development process. Its specific action and lack of non-target toxicity make it a safe and powerful tool in our arsenal.

Excellent

The targeted DNA damage capability of the anti-HIgG(Fc)Fab-C-DMDM ADC has drastically improved the selectivity and efficacy of our cytotoxic studies. It's a pivotal resource for developing more effective ADCs.

Excellent

Using the anti-HIgG(Fc)Fab-C-DMDM ADC has allowed us to push forward in our ADC research with more confidence. The specific binding to the Fc region and subsequent DNA damage is impressively consistent.

Q: 1: What research is being done to improve the understanding of this ADC's mechanism?
A: Ongoing studies focus on detailing the interaction of the ADC with target cells, the pathways of DNA damage induced by DMDM, and the overall therapeutic window of the ADC in various models.
Q: 2: How does this ADC compare to full antibody ADCs in terms of therapeutic potential?
A: While potentially less immunogenic and more tissue-penetrant, Fab-based ADCs might exhibit different efficacy and dosing profiles compared to full antibody ADCs.
Q: 3: What future modifications could enhance the performance of this ADC?
A: Future enhancements could include optimizing the linker technology for more precise drug release or modifying the Fab fragment to improve targeting accuracy.
Q: 4: How is the stability of this ADC ensured during storage and transport?
A: The ADC must be stored under conditions that maintain the integrity of the antibody and the linker, typically requiring refrigeration and protection from light.
Q: 5: What are potential challenges in developing Fab fragment-based ADCs?
A: Challenges include ensuring the stability of the Fab fragment during conjugation, maintaining its specificity and binding affinity, and managing the overall immunogenicity of the construct.
Q: 6: How could the development of resistance to DMDM be addressed in therapeutic applications?
A: Strategies might include combination therapy with other agents to target multiple pathways, or developing ADCs with different mechanisms of action to circumvent resistance.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-055	Protein A-Duocarmycin ADC		Duocarmycins
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-050	Protein G-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-003	anti-HIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
WJY-0423-LS107	Protein A-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-044	anti-Rat IgG(Fc)Fab-C-DMDM ADC	Cleavable linkers	DMDM (duocarmycin DM)
ADC-AA-030	anti-MIgG(Fc)Fab-C-DMDM ADC	Cleavable linkers	DMDM (duocarmycin DM)
ADC-AA-024	anti-MIgG(Fc)-C-DMDM ADC	Cleavable linkers	DMDM (duocarmycin DM)
ADC-AA-006	anti-HIgG(Fc)-C-DMDM ADC	Cleavable linkers	DMDM (duocarmycin DM)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.